相似文献
1
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.
Vaccine. 2009 Jun 2;27(27):3598-604. doi: 10.1016/j.vaccine.2009.03.058. Epub 2009 Apr 9.
2
An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.
Infect Immun. 2014 Oct;82(10):4080-91. doi: 10.1128/IAI.01950-14. Epub 2014 Jul 14.
3
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Infect Immun. 2012 Aug;80(8):2678-88. doi: 10.1128/IAI.00215-12. Epub 2012 May 21.
4
Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A.
Infect Immun. 2003 Mar;71(3):1608-10. doi: 10.1128/IAI.71.3.1608-1610.2003.
5
Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
Infect Immun. 2011 Jun;79(6):2295-302. doi: 10.1128/IAI.00130-11. Epub 2011 Apr 11.
6
Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity.
Toxins (Basel). 2014 Apr 22;6(4):1385-96. doi: 10.3390/toxins6041385.
7
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
BMC Infect Dis. 2016 Oct 22;16(1):596. doi: 10.1186/s12879-016-1924-1.
8
Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A.
Infect Immun. 1999 May;67(5):2145-52. doi: 10.1128/IAI.67.5.2145-2152.1999.
9
A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.
Vaccine. 2012 Jun 13;30(28):4249-58. doi: 10.1016/j.vaccine.2012.04.045. Epub 2012 Apr 23.
10
Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B.
Hum Vaccin Immunother. 2013 Jan;9(1):63-73. doi: 10.4161/hv.22434. Epub 2012 Nov 10.
引用本文的文献
1
Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations.
Front Immunol. 2025 May 14;16:1584876. doi: 10.3389/fimmu.2025.1584876. eCollection 2025.
2
Immunization Strategies Against Clostridioides difficile.
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.
3
Major pathogenic in human and progress toward the clostridial vaccines.
Iran J Basic Med Sci. 2022 Sep;25(9):1059-1068. doi: 10.22038/IJBMS.2022.65518.14417.
4
Host Immune Responses to : Toxins and Beyond.
Front Microbiol. 2021 Dec 21;12:804949. doi: 10.3389/fmicb.2021.804949. eCollection 2021.
5
A Replicating Single-Cycle Adenovirus Vaccine Effective against .
Vaccines (Basel). 2020 Aug 22;8(3):470. doi: 10.3390/vaccines8030470.
6
Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027.
mSphere. 2019 Oct 2;4(5):e00596-19. doi: 10.1128/mSphere.00596-19.
7
The role of toxins in Clostridium difficile infection.
FEMS Microbiol Rev. 2017 Nov 1;41(6):723-750. doi: 10.1093/femsre/fux048.
8
Conventional and alternative treatment approaches for infection.
Int J Health Sci (Qassim). 2017 Jan-Mar;11(1):1-10.
9
A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection.
Infect Dis Ther. 2017 Mar;6(1):1-35. doi: 10.1007/s40121-016-0140-z. Epub 2016 Dec 1.
10
A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
BMC Infect Dis. 2016 Oct 22;16(1):596. doi: 10.1186/s12879-016-1924-1.
本文引用的文献
1
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.
Vaccine. 2008 Jun 25;26(27-28):3404-9. doi: 10.1016/j.vaccine.2008.04.042. Epub 2008 May 7.
2
Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant.
J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):403-11. doi: 10.1097/QAI.0b013e3181651b9d.
3
Use of attenuated bacteria as delivery vectors for DNA vaccines.
Expert Rev Vaccines. 2007 Feb;6(1):97-110. doi: 10.1586/14760584.6.1.97.
4
Vaccine delivery methods using viral vectors.
Mol Pharm. 2007 Jan-Feb;4(1):18-32. doi: 10.1021/mp060098+.
5
Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier.
World J Gastroenterol. 2006 Dec 28;12(48):7774-8. doi: 10.3748/wjg.v12.i48.7774.
6
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
J Immunol. 2007 Jan 15;178(2):1059-67. doi: 10.4049/jimmunol.178.2.1059.
7
Leishmania major soluble exo-antigens (LmSEAgs) protect neonatal BALB/C mice from a subsequent challenge with L. major and stimulate cytokine production by Leishmania-naïve human peripheral blood mononuclear cells.
J Parasitol. 2006 Oct;92(5):971-6. doi: 10.1645/GE-782R.1.
8
Needle-free liquid jet injections: mechanisms and applications.
Expert Rev Med Devices. 2006 Sep;3(5):565-74. doi: 10.1586/17434440.3.5.565.
9
Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases.
Methods. 2006 Sep;40(1):86-97. doi: 10.1016/j.ymeth.2006.05.022.
10
Delivery of DNA vaccines using electroporation.
Methods Mol Med. 2006;127:73-82. doi: 10.1385/1-59745-168-1:73.
Zotero 插件